Wells Fargo & Company Reaffirms Equal Weight Rating for Arcellx (NASDAQ:ACLX)

Arcellx (NASDAQ:ACLX)‘s stock had its “equal weight” rating reaffirmed by equities researchers at Wells Fargo & Company in a note issued to investors on Monday,Benzinga reports. They currently have a $115.00 target price on the stock. Wells Fargo & Company‘s price objective suggests a potential upside of 0.87% from the company’s current price.

Several other equities analysts have also commented on the stock. Guggenheim reiterated a “buy” rating on shares of Arcellx in a research note on Monday, November 24th. Citigroup restated a “buy” rating on shares of Arcellx in a research note on Monday, November 24th. Rothschild & Co Redburn downgraded Arcellx from a “buy” rating to a “neutral” rating and set a $82.00 price objective for the company. in a report on Thursday, February 12th. Wolfe Research began coverage on shares of Arcellx in a research report on Tuesday, November 18th. They issued a “peer perform” rating for the company. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $115.00 target price on shares of Arcellx in a report on Wednesday, February 4th. Eight investment analysts have rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Arcellx has a consensus rating of “Moderate Buy” and an average price target of $110.70.

Arcellx Price Performance

Arcellx stock opened at $114.01 on Monday. The stock’s fifty day moving average is $66.98 and its two-hundred day moving average is $74.77. The stock has a market cap of $6.59 billion, a PE ratio of -29.01 and a beta of 0.36. Arcellx has a 1-year low of $47.86 and a 1-year high of $114.37.

Insider Buying and Selling

In other Arcellx news, insider Christopher Heery sold 5,882 shares of the company’s stock in a transaction dated Wednesday, January 14th. The shares were sold at an average price of $68.51, for a total transaction of $402,975.82. Following the transaction, the insider directly owned 23,749 shares in the company, valued at approximately $1,627,043.99. This represents a 19.85% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Insiders have sold a total of 19,450 shares of company stock worth $1,283,477 over the last quarter. 8.35% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Arcellx

Several institutional investors and hedge funds have recently made changes to their positions in the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in shares of Arcellx by 5.1% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 28,753 shares of the company’s stock worth $1,893,000 after purchasing an additional 1,390 shares during the period. Empowered Funds LLC purchased a new position in Arcellx during the first quarter worth about $1,768,000. Intech Investment Management LLC boosted its stake in Arcellx by 27.7% in the 1st quarter. Intech Investment Management LLC now owns 21,967 shares of the company’s stock worth $1,441,000 after buying an additional 4,760 shares during the last quarter. Teacher Retirement System of Texas boosted its stake in Arcellx by 1.7% in the 2nd quarter. Teacher Retirement System of Texas now owns 8,883 shares of the company’s stock worth $585,000 after buying an additional 151 shares during the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. purchased a new stake in Arcellx in the 2nd quarter valued at about $563,000. 96.03% of the stock is currently owned by hedge funds and other institutional investors.

More Arcellx News

Here are the key news stories impacting Arcellx this week:

• Positive Sentiment: Gilead agreed to buy Arcellx for $115 per share in cash plus a $5 contingent value right (CVR), valuing the company at about $7.8 billion — a deal that triggered the pre-market rally because it provides a clear, immediate cash exit for ACLX shareholders and validates Arcellx’s Anito‑cel program. Gilead Sciences to Acquire Arcellx to Maximize Long-term Potential of Anito-cel
• Positive Sentiment: Strategic rationale: Gilead is buying Arcellx to strengthen its oncology portfolio and capture the long‑term potential of Anito‑cel, which investors interpret as product and pipeline validation that supports a takeover premium. Gilead Sciences to Buy Arcellx in Deal Valued at $7.8 Billion
• Neutral Sentiment: Deal mechanics: the headline $115 cash + $5 CVR structure is milestone‑linked (CVR pays only if targets are met); closing is subject to customary conditions — meaning final payoff to shareholders depends on future milestones and regulatory approvals. Gilead to acquire cancer therapy developer Arcellx for up to $7.8 billion
• Neutral Sentiment: Market reaction context: multiple outlets report a very large pre-market spike after the announcement; intraday trading has since normalized/pulled back as investors digest the terms and potential timing for closing. Why did ACLX stock surge 80% in pre-market today?
• Negative Sentiment: A shareholder law firm (Halper Sadeh LLC) has opened an investigation into whether the $115 + $5 CVR package is a fair price for Arcellx shareholders, introducing the possibility of litigation or pushback that could complicate or delay the deal. ACLX Stock Alert: Halper Sadeh LLC is Investigating Whether Arcellx, Inc. is Obtaining a Fair Price for its Shareholders
• Negative Sentiment: Pre-deal selling by large holders (Perceptive Advisors sold roughly 1M shares in Q4) and recent competitive/rival drug developments had pressured the stock earlier — factors that could influence shareholder sentiment about the adequacy of the offer. $80 Million Arcellx Sale Follows Steep Stock Drop as Rival Drug Emerges

Arcellx Company Profile

Arcellx, Inc (NASDAQ: ACLX) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of next-generation cell therapies for oncology and autoimmune diseases. The company’s proprietary ARC-SparX™ platform is designed to enable precise control over cell-surface receptor activation and to improve the safety, efficacy and durability of adoptive cell therapies. Leveraging this technology, Arcellx engineers immune cells with modular antigen-binding domains that can be exchanged to target a variety of disease-associated markers.

The company’s pipeline comprises multiple wholly owned programs in hematologic malignancies and solid tumors at various stages of preclinical and clinical development.